Health Innovation For Prevention And Precision At Scale — Dr. Päivi Sillanaukee, MD, Ph.D. — Special Envoy, Health & Wellbeing, Ministry of Social Affairs and Health Finland.

Dr. Päivi Sillanaukee, MD, Ph.D. is Special Envoy for Health and Wellbeing, Ministry of Social Affairs and Health Finland (https://stm.fi/en/rdi-growth-programm…).

Dr. Sillanaukee has over 20 years of experience at highest civil servant administrative positions, both from government, including roles as Director General at Ministry of Social Affairs and Health, Ambassador for Health and Wellbeing at the Ministry for Foreign Affairs, as well as various additional roles in the public sector at the Municipalities and Special Health care district levels.

Actively participating also in Global Health, Dr. Sillanaukee has chaired and facilitated global multisectoral, multi-partner Health Security collaborations, facilitating capacity building at the country level. She served as Vice chair and member of WHO Executive Board, as Executive President for WHO/Europe Regional Committee, Member of Women in Global Health advocating for Gender Equity in Health, a member of Global Pulse Finland’s health sector advisory board, as Member of Board of Directors, Healthcare Information and Management Systems Society (HIMSS) and Member of the Inaugural Board of Digital Health \& AI Research Collaborative (I-DAIR).

Dr. Sillanaukee has also served as the co-chair of the Alliance for Health Security Cooperation (AHSC) and a member of the Steering Group of the Global Health Security Agenda.

Dr. Sillanaukee is skilled in Health Care and Social Affairs management, Health and social service management, Health Security, Universal Health Coverage, Integrated care, Communicable \& Noncommunicable diseases, Government, Management, Health Technology \& innovation, Entrepreneurship, Quality Management, Interpersonal Skills, Non-profit and for profit Boards.

Dr. Sillanaukee graduated with an MD, PhD, and eMBA from University of Tampere, specialization for Public Health Management, and an Honorary Doctor from University of Helsinki Faculty of Medicine. She also studied humanities and cultural sciences in University of Jyväskylä

#PaiviSillanaukee #Finland #Healthcare #Ambassador #ForeignAffairs #SocialAffairs #HealthSecurity #UniversalHealthCoverage #IntegratedCare #CommunicableDiseases #Wellbeing #NoncommunicableDiseases #AgingInPlace #OneHealth #SilverEconomy #HealthTechnology #Entrepreneurship #QualityManagement #HIMSS #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

The future of therapeutic apheresis & transfusion medicine — dr. tina ipe, MD, MPH — CEO, regen med clinic.

Dr. Tina Ipe, MD, MPH is Chief Executive Officer at Regen Med Clinic (https://www.regenmed.vip/), a medical practice which provides multi-specialty infusions, cutting-edge treatments such as therapeutic apheresis (plasmapheresis and collections), as well as novel aesthetic treatments, for patients with a variety chronic illnesses.

Dr. Ipe is a board-certified physician and clinical researcher. Before entering private practice, she was Chief Medical Officer at the Oklahoma Blood Institute, Associate Medical Director at Houston Methodist Hospital, and Division Director at University of Arkansas for Medical Sciences (UAMS). She is an expert in the fields of blood disorders, immunology, therapeutic apheresis, blood banking, and transfusion medicine. She has published more than 50 peer-reviewed manuscripts and book chapters.

Dr. Ipe received her medical degree from the Medical College of Virginia and completed her residency in clinical pathology and fellowship in transfusion medicine at the Hospital of the University of Pennsylvania. She also has an MPH from Dartmouth.

#TinaIpe #BloodDisorders #Blood #Biotherapies #Immunology #TherapeuticApheresis #BloodBanking #TransfusionMedicine #RegenerativeMedicine #TherapeuticPlasmaExchange #ConvalescentPlasma #ExtracorporealPhotopheresis #Parabiosis #Longevity #Aging #HospiceCare #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Science And Engineering For Humanity — Dr. David Agus, MD — Founding Director & Co-CEO, Ellison Institute of Technology.

Dr. David B. Agus (https://davidagus.com/) is one of the world’s leading doctors and pioneering biomedical researchers.

Dr. Agus is the Founding Director and Co-CEO of the Ellison Institute of.
Technology (https://eit.org/) and a professor of medicine (https://keck.usc.edu/faculty-search/d…) and engineering (https://viterbi.usc.edu/directory/fac…) the University of.
Southern California.

A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers.
dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs.

An international leader in global health and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and is co-chair of the Global Health Security Consortium (https://institute.global/tags/global–…). He is also a CBS News contributor.

Dr. Agus’ three books The End of Illness, A Short Guide to a Long Life and The Lucky Years: How to Thrive in the Brave New World of Health are all New York Times and international bestsellers. His latest book, The Book of Animal.
Secrets: Nature’s Lessons for a Long and Happy Life, was released in December 2023. He is a 2017 recipient of the Ellis Island Medal of Honor.

#DavidAgus #LawrenceEllison #LarryEllison #TonyBlair #ShinyaYamanaka #ArtificialIntelligence #Health #MedicalScience #FoodSecurity #SustainableAgriculture #ClimateChange #CleanEnergy #DrugDiscovery #MolecularAnalytics #Microenvironment #Cancer #Oncology #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Protecting Human And Animal Health — Dr. Tristan Colonius, DVM — Chief Veterinary Officer & Deputy Director for Science Policy, Center for Veterinary Medicine (CVM), U.S. Food and Drug Administration (FDA)

Dr. Tristan Colonius, DVM is the Chief Veterinary Officer and Deputy Director for Science Policy at FDA’s Center for Veterinary Medicine (CVM — https://www.fda.gov/animal-veterinary).

Dr. Colonius previously worked in various positions at FDA, including as Deputy Chief of Staff to Commissioner Dr. Robert Califf and as an International Policy Analyst.

During his career at FDA, Dr. Colonius has been working on numerous initiatives including the Animal and Veterinary Innovation Agenda, One Health, Intentional Genomic Alterations in animals, and zootechnical animal feed substances (ZAFS) among many other programs at CVM.

Prior to joining FDA, Dr. Colonius held positions in the US Senate and US Department of Agriculture.

Dr. Colonius came to the Hill as an American Association for the Advancement of Science (AAAS) Science and Technology fellow in 2012 in Senator Kirsten Gillibrand’s (NY) office and worked to help pass the Agricultural Act of 2014 (the “Farm Bill”) renewal.

Dr. Colonius then went to work for Senator Diane Feinstein, first as a Legislative Assistant and then as her Deputy Legislative Director. While in Senator Feinstein’s office, Dr. Colonius worked on disaster preparedness, climate resiliency, emerging public health threats, homeland security, federal science policy, and animal welfare/conservation.

Dr. Colonius holds a BA in Political Science and Doctor of Veterinary Medicine from Louisiana State University, as well as a Master of Public Administration from the University of Illinois.

Mike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. (https://nervgen.com/), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.

NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Mr. Kelly brings three decades of pharmaceutical experience playing instrumental roles in the creation, development and strengthening of several companies.

Most recently, Mr. Kelly served as President of US Operations for Adapt Pharma, Inc. from March 2016 to June 2019, and played a key leadership role in the development and commercialization of NARCAN (naloxone HCl) Nasal Spray in the US and Canada and in the eventual sale to Emergent BioSolutions for US$735 million.

Prior to his tenure at Adapt Pharma, Inc., Mr. Kelly served as the Chief Executive Officer and a Director of Covis Pharmaceuticals, Inc., where, along with its European affiliate, grew and sold the company assets for US$1.2 billion. Mr. Kelly was also a member of the founding management team of Azur Pharma Limited, a specialty pharmaceutical company, and later, following a strategic merger, served as the Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals Inc. Mr. Kelly has also held various commercial and medical roles at Guilford Pharmaceuticals Inc., ViroPharma Incorporated and TAP Pharmaceuticals Inc. and has been a Director of ARS Pharmaceuticals Inc. since May 2019.

Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University.

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Next Generation Biomanufacturing Technologies — Dr. Leonard Tender, Ph.D. — Biological Technologies Office, Defense Advanced Research Projects Agency — DARPA

Dr. Leonard Tender, Ph.D. is a Program Manager in the Biological Technologies Office at DARPA (https://www.darpa.mil/staff/dr-leonar…) where his research interests include developing new methods for user-defined control of biological processes, and climate and supply chain resilience.

Prior to coming to DARPA, Dr. Tender was a principal investigator and led the Laboratory for Molecular Interfaces in the Center for Bio/Molecular Science and Engineering at the U.S. Naval Research Laboratory. There, among other accomplishments, he facilitated numerous international collaborations with key external stakeholders in academia, industry, and government and his highly interdisciplinary research team, comprised of electrochemists, microbiologists, and engineers, is widely recognized for its many contributions to the field of microbial electrochemistry.

Dr. Tender earned a doctorate degree in analytical chemistry from the University of North Carolina, Chapel Hill; a bachelor’s degree in chemistry from the Massachusetts Institute of Technology; completed a post-doctoral fellowship in the Department of Chemistry from the University of California, Berkeley; and served as a visiting scientist in the Stanford University Department of Chemistry.

Dr. Tender co-founded the International Society for Microbial Electrochemistry and Technology and is a recipient of the Arthur S. Flemming Award, which honors outstanding federal employees, by the George Washington University’s Trachtenberg School of Public Policy and Public Administration.

#DARPA #Biomanufacturing #QuantumBiology #QuantumComputing #NavalResearchLaboratory #MicrobialElectrochemistry #DefenseAdvancedResearchProjectsAgency #Bioelectronics #TissueRegeneration #UnderseaEnergy #BreathableArmors #EdibleMacronutrients #Lubricants #Adhesives #TacticalFibers #PotableWater #Plastic #OrbitalManufacturing #Extremophiles #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Expanding Healthy Human Lifespan for All — Dr. Mehmood Khan, MD — CEO, Hevolution Foundation.

Dr. Mehmood Khan, MD is the Chief Executive Officer of Hevolution Foundation (https://www.hevolution.com/), a first of its kind non-profit organization that funds research through grants and provides investments in biotech to incentivize healthspan science across disciplines and borders for the benefit of all. Established by a Saudi Royal Decree, with its headquarters in Riyadh, with additional international hubs to support the expansion and execute the global mission, it’s vision is to expand healthy human lifespan for the benefit of all humanity.

Hevolution Foundation aims to be positioned as a global leader, catalyst, partner, and convener, to increase the number of scientists entering the field, to increase the investable opportunities in the field of aging, and to help shape the regulatory and government environment.

Dr. Khan also currently serves as the Executive Chairman of Life Biosciences Inc. where he joined the company in April 2019 as the Chief Executive Officer and Board Member. Life Biosciences was founded to advance scientific research and develop innovative new therapies to improve and extend healthy lives for everyone.

Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R\&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo’s global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share.

Prior to joining PepsiCo, Dr. Khan served as President of Global R\&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue.

Before moving into industry, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition in Minneapolis, MN.

Dr. Khan is currently a member of the Board of Directors of Reckitt Benckiser.